An orally administered butyrate‐releasing derivative reduces neutrophil recruitment and inflammation in dextran sulphate sodium‐induced murine colitis
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Background and Purpose: Butyrate has shown benefits in inflammatory bowel diseases. However, it is not often administered orally because of its rancid smell and unpleasant taste. The efficacy of a more palatable butyrate‐releasing derivative, N‐(1‐carbamoyl‐2‐phenylethyl) butyramide (FBA), was evaluated in a mouse model of colitis induced by dextran sodium sulphate (DSS). Experimental Approach: Male 10 week‐old BALB/c mice received DSS (2.5%) in drinking water (for 5 days) followed by DSS‐free water for 7 days (DSS group). Oral FBA administration (42.5 mg·kg−1) was started 7 days before DSS as preventive (P‐FBA), or 2 days after DSS as therapeutic (T‐FBA); both treatments lasted 19 days. One DSS‐untreated group received only tap water (CON). Key Results: FBA treatments reduced colitis symptoms and colon damage. P‐FBA and T‐FBA significantly decreased polymorphonuclear cell infiltration score compared with the DSS group. FBA reversed the imbalance between pro‐ and anti‐inflammatory cytokines (reducing inducible NOS protein expression, CCL2 and IL‐6 transcripts in colon and increasing TGFβ and IL‐10). Morever, P‐FBA and T‐FBA limited neutrophil recruitment (by expression and localization of the neutrophil granule protease Ly‐6G), restored deficiency of the butyrate transporter and improved intestinal epithelial integrity, preventing tight‐junction impairment (zonulin‐1 and occludin). FBA, similar to its parental compound sodium butyrate, inhibited histone deacetylase‐9 and restored H3 histone acetylation, exerting an anti‐inflammatory effect through NF‐κB inhibition and the up‐regulation of PPARγ. Conclusions and Implications: FBA reduces inflammatory intestinal damage in mice indicating its potential as a postbiotic derivative without the problems associated with the oral administration of sodium butyrate. Linked Articles: This article is part of a themed section on Principles of Pharmacological Research of Nutraceuticals. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.11/issuetoc
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell Homeostasis
Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlooly-Y, M., Glickman, J. N., & Garrett, W. S. (2013) · Science · doi:10.1126/science.1241165 · Cited by 5,413
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00872.x · Cited by 3,625
Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43
Maslowski, K. M., Vieira, A. T., Ng, A., Kranich, J., Sierro, F., Yu, D., Schilter, H. C., Rolph, M. S., Mackay, F., Artis, D., et al. (2009) · Nature · doi:10.1038/nature08530 · Cited by 3,241 · cited 1×
“Among SCFAs, butyrate can influence chemotaxis of immune cells through FFA2 receptors, but this effect depends on the type of immune cells and butyrate concentration (Maslowski et al., 2009; Sina et al., 2009).”
BackgroundReview article: the role of butyrate on colonic function
HAMER, H. M., JONKERS, D., VENEMA, K., VANHOUTVIN, S., TROOST, F. J., & BRUMMER, R. ‐. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03562.x · Cited by 2,721
Singh, N., Gurav, A., Sivaprakasam, S., Brady, E., Padia, R., Shi, H., Thangaraju, M., Prasad, P. D., Manicassamy, S., Munn, D. H., et al. (2014) · Immunity · doi:10.1016/j.immuni.2013.12.007 · Cited by 2,368 · cited 2×
“, 2013) and together with GPR109A are considered the main butyrate targets involved in the suppression of colonic inflammation and carcinogenesis (Singh et al., 2014).”
BackgroundChang, P. V., Hao, L., Offermanns, S., & Medzhitov, R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322269111 · Cited by 2,175 · cited 4×
“Following haematoxylin and eosin (H&E) staining, colon sections were analysed in a blinded manner for the evaluation of the histopathological score as previously described (Chang et al., 2014).”
BackgroundMethodResultInfluentialPeng, L., Li, Z.-R., Green, R. S., Holzmanr, I. R., & Lin, J. (2009) · The Journal of Nutrition · doi:10.3945/jn.109.104638 · Cited by 2,130 · cited 1×
“SCFAs modulate key epithelial cell functions that help tomaintain intestinal epithelial barrier integrity preventing injury (Peng et al., 2009).”
BackgroundAnimal Research: Reporting in vivo Experiments—The ARRIVE Guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.220 · Cited by 2,012
Potential beneficial effects of butyrate in intestinal and extraintestinal diseases
Canani, R. B. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i12.1519 · Cited by 1,381
Self-citationMcGrath, J. C., & Lilley, E. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12955 · Cited by 1,321
Cited by
Human gut microbiota/microbiome in health and diseases: a review
Gomaa, E. Z. (2020) · Antonie van Leeuwenhoek · doi:10.1007/s10482-020-01474-7 · Cited by 1,294
The gut microbiome: Relationships with disease and opportunities for therapy
Durack, J., & Lynch, S. V. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20180448 · Cited by 943
van de Wouw, M., Boehme, M., Lyte, J. M., Wiley, N., Strain, C., O'Sullivan, O., Clarke, G., Stanton, C., Dinan, T. G., & Cryan, J. F. (2018) · The Journal of Physiology · doi:10.1113/jp276431 · Cited by 789
“This was reversed by SCFA treatment, which is not surprising as SCFAs have previously been shown to restore intestinal permeability (Kelly et al. 2015; Tong et al. 2016; Simeoli et al. 2017).”
BackgroundChen, G., Ran, X., Li, B., Li, Y., He, D., Huang, B., Fu, S., Liu, J., & Wang, W. (2018) · eBioMedicine · doi:10.1016/j.ebiom.2018.03.030 · Cited by 580
“…piglets (Huang et al., 2015), promoting the recovering of intestinal wound healing through its positive effect on the tight junctions (Ma et al., 2012) and butyratereleasing derivativesmaintain proper Zo1 andOcln expression in the colons of patientswithDSS-induced colitis (Simeoli et al., 2017).”
BackgroundGut microbiota-derived short-chain fatty acids and their role in human health and disease
Mukhopadhya, I., & Louis, P. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01183-w · Cited by 501
Chen, D., Jin, D., Huang, S., Wu, J., Xu, M., Liu, T., Dong, W., Liu, X., Wang, S., Zhong, W., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.11.019 · Cited by 495
Zeng, H., Umar, S., Rust, B., Lazarova, D., & Bordonaro, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051214 · Cited by 480
Microbiota-gut-brain axis: Modulator of host metabolism and appetite
van de Wouw, M., Schellekens, H., Dinan, T. G., & Cryan, J. F. (2017) · The Journal of Nutrition · doi:10.3945/jn.116.240481 · Cited by 461
Gut microbiota-derived short chain fatty acids are potential mediators in gut inflammation
Akhtar, M., Chen, Y., Ma, Z., Zhang, X., Shi, D., Khan, J. A., & Liu, H. (2022) · Animal Nutrition · doi:10.1016/j.aninu.2021.11.005 · Cited by 363
Mollica, M. P., Mattace Raso, G., Cavaliere, G., Trinchese, G., De Filippo, C., Aceto, S., Prisco, M., Pirozzi, C., Di Guida, F., Lama, A., et al. (2017) · Diabetes · doi:10.2337/db16-0924 · Cited by 356
Self-citationHou, H., Chen, D., Zhang, K., Zhang, W., Liu, T., Wang, S., Dai, X., Wang, B., Zhong, W., & Cao, H. (2022) · Cancer Letters · doi:10.1016/j.canlet.2021.11.027 · Cited by 263
Lee, C., Kim, B. G., Kim, J. H., Chun, J., Im, J. P., & Kim, J. S. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.07.023 · Cited by 260
Recharla, N., Geesala, R., & Shi, X.-Z. (2023) · Nutrients · doi:10.3390/nu15102275 · Cited by 256
Principles of pharmacological research of nutraceuticals
Andrew, R., & Izzo, A. A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13779 · Cited by 170
“This review is complemented by a further original article demonstrating, in mouse models, the use of butyrate in a derivative form to deliver an unpalatable agent to the inflamed colon (Simeoli et al., 2017).”
BackgroundPhytochemicals as modifiers of gut microbial communities
Dingeo, G., Brito, A., Samouda, H., Iddir, M., La Frano, M. R., & Bohn, T. (2020) · Food & Function · doi:10.1039/d0fo01483d · Cited by 164
Pan, X., Fang, X., Wang, F., Li, H., Niu, W., Liang, W., Wu, C., Li, J., Tu, X., Pan, L., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14806 · Cited by 151
“, 2018) and in mice with colitis (Simeoli et al., 2017), where butyrate treatment reduced the infiltration of neutrophils into injured tissues.”
BackgroundCan we ‘seize’ the gut microbiota to treat epilepsy?
De Caro, C., Iannone, L. F., Citraro, R., Striano, P., De Sarro, G., Constanti, A., Cryan, J. F., & Russo, E. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.10.002 · Cited by 110
Metadata
- Authors
- Simeoli, R., Mattace Raso, G., Pirozzi, C., Lama, A., Santoro, A., Russo, R., Montero‐Melendez, T., Berni Canani, R., Calignano, A., Perretti, M., & Meli, R.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2016-11-03
- Volume
- 174
- Issue
- 11
- Pages
- 1484-1496
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2528822221
- Cited by
- 134
- References
- 15
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.